Piramal Pharma informs about outcome of board meeting

29 Jan 2026 Evaluate

With reference to its letter dated 16th January, 2026. Pursuant to Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Piramal Pharma has informed that the Board of Directors of the Company at its meeting held today, 28th January, 2026, has approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2025. In this regard, it has enclosed the following: a. Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2025; b. Limited Review Reports by the Statutory Auditor. Further, the company is arranging to publish details of the above-mentioned financial results in newspapers as per Regulation 47 of the SEBI Listing Regulations. The above information is also available on the website of the Company at www.piramalpharma.com. The meeting of the Board commenced at 5:30 pm and concluded at 10.00 pm.

The above information is a part of company’s filings submitted to BSE.

Piramal Pharma Share Price

151.60 -2.95 (-1.91%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×